慢性乙型肝炎病毒感染患者血清YKL-40水平与肝纤维化的临床分析

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎患者血清YKL-40水平表达与肝纤维化程度的关系。方法随机选取健康体检人员20名和慢性乙型肝炎患者94例,测定血清YKL-40水平。根据肝组织活检的病理学纤维化程度分为S1-S4期,另根据纤维化分期分为两组,A1组1≤S<3,A2组3≤S≤4,进行组间比较。结果 A1组血清YKL-40水平低于A2组（44.93± 27.91对75.67±51.40）,差异有统计学意义（P<0.05）;S1期和S2期患者血清YKL-40差异无统计学意义（33.50± 20.63对48.93±29.43,P>0.05）;S3期和S4期患者血清YKL-40差异无统计学意义（74.87±51.22对76.63±57.66,P>0.05）。结论不同肝脏纤维化程度的慢性HBV感染患者之间血清YKL-40水平可能存在差异,血清YKL-40水平可以预测区别轻度与中重度肝纤维化,中重度肝纤维化患者血清YKL-40水平较高。

曹欣, 关玉娟, 陈美娟. 慢性乙型肝炎病毒感染患者血清YKL-40水平与肝纤维化的临床分析[J]. 肝脏, 2016, 21(1): 57-59.

参考文献

1 Poynard T,Mathurin P,Lai CL,et al.Acomparison of fibrosis progression in chronic liver diseases. JHepatol,2003,38:257-265.
2 Lee KG,Seo YS,An H,et al.Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B.JGastroenterol Hepatol,2010,25:94-100.
3 Rockey DC,Bissell DM.Noninvasive measures of liver fibrosis. Hepatology,2006,43(2 Suppl 1):S113-120.
4 Fontana RJ,Litman HJ,Dienstag JL,et al.YKL-40 genetic poly Morphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int,2012,32:665-674.
5 刘勇鹏,张琳.Fibroscan对HBV感染者肝纤维化诊断的临床研究.中国医药导报,2011,8:42-43.
6 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版).中华肝脏病杂志,2011,19:13-24.
7 刘平,慕永平,刘成海.加强肝纤维化的诊断与治疗研究.中华肝脏病杂志,2012,20:561-562.
8 Bataller R,Brenner D.Liver fibrosis.JClin Invest,2005,115:209-218.
9 Scott DR,Levy MT.Liver transient elastography(FibroScan):a place in the management algorith ms of chronic viral hepatitis. Antivir Ther,2010,15:1-11.
10 Tsochatzis EA,Gurusa My KS,Ntaoula S,et al.Elastography for the diagnosis of severity of fibrosis in chronic liver disease:a metaanalysis of diagnosis accuracy.JHepatol,2011,54:650-659.
11 Rathcke CN,Holm kvist J,Husm oen LL,et al. Association of poly Morphisms of the CHI3 L1 gene with asth ma and atopy:a populations-based study of 6514 Danish adults. PLoSOne,2009,4:e6106.
12 Dolganiuc A,Chang S,Kodys K,et al.Hepatitis Cvirus(HCV)core protein-induced,Monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCVinfection.JIm Munol,2006,177:6758-6768.
13 Zhang YX,Wu WJ,Zhang YZ,et al.Noninvasive assessment of liver fibrosis with combined seru Ma minotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B. World JGastroenterol,2008,14:7117-7121.
14 Eurich D,Neu Mann UP,Boas-Knoop S,et al.YKL-40-gene poly Morphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis Cvirus-induced liver disease.JGastroenterol Hepatol,2013,28:153-160.
15 Fontana RJ,Dienstag JL,Bonkovsky HL,et al.Seru Mfibrosis markers are associated with liver disease progression in nonresponder patients with chronic hepatitis C. Gut,2010,59:1401-1409.
16 Schiavon LL,Carvalho-Filho RJ,Narciso-Schiavon JL,et al.YKL-40 and hyaluronic acid(HA)as noninvasive markers of liver fibrosis in kidney transplant patients with HCVchronic infection. Scand JGastroenterol,2010,45:615-622.

[1]	宁惠明, 徐燕华. 非酒精性脂肪性肝病患者血清视黄醛结合蛋白4的变化及临床意义[J]. 肝脏, 2020, 25(4): 429-432.
[2]	卢君瑶, 王登宇, 尹东林, 白玉盘, 许洁. HBV相关肝细胞癌的临床特征及危险因素分析[J]. 肝脏, 2020, 25(3): 285-287.
[3]	沈张平, 王钦君, 季沈杰. 血清miR127-3P与原发性肝癌的相关性研究[J]. 肝脏, 2020, 25(3): 302-305.
[4]	薛宏丽. HBsAg定量在慢性乙型肝炎治疗中的意义[J]. 肝脏, 2020, 25(3): 308-310.
[5]	梅栖榕, 杨丽, 沈毅. 慢性乙型肝炎患者长期服用阿德福韦酯与肾性低磷血症的相关性[J]. 肝脏, 2020, 25(3): 311-313.
[6]	孔媛媛, 魏巍, 单姗, 马红, 欧晓娟, 徐小元, 段钟平, 侯金林, 魏来, 尤红, 贾继东, 中国消除乙肝临床科研平台(CR-HepB)研究组. 乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化[J]. 肝脏, 2020, 25(2): 123-127.
[7]	江海洋, 顾生旺, 刘欢, 姬腾飞, 蒋兆荣, 吴刚, 穆小苏. 基于1 783例慢性乙型肝炎患者长期随访的结果对大幅度提高其临床治愈的思考[J]. 肝脏, 2020, 25(2): 169-171.
[8]	陈攀丽, 唐建荣, 付雪芹, 张逸强, 胡景岚, 吴小力. Hp阳性监测在慢性乙型肝炎合并消化性溃疡患者中的临床意义[J]. 肝脏, 2020, 25(2): 184-185.
[9]	黄菁, 张永臣, 虞玲. 外周血Th17相关炎性因子在慢性乙型肝炎患者接受Peg-IFNα治疗前后的变化及临床意义[J]. 肝脏, 2020, 25(2): 194-196.
[10]	马春明, 张锁才, 史罗明, 吴剑明, 周根法, 郑剑. 慢性乙型肝炎初治后转换恩替卡韦干预的耐药及疗效观察[J]. 肝脏, 2020, 25(2): 208-211.
[11]	马春明, 张锁才, 史罗明, 吴剑明, 周根法, 郑剑. 慢性乙型肝炎外周血浆样树突状细胞与免疫应答的关系及干预分析[J]. 肝脏, 2020, 25(1): 34-35.
[12]	张郴华, 钟备, 邓英, 李敏. 慢性乙型肝炎患者HBV核苷(酸)类似物预存耐药基因突变的研究[J]. 肝脏, 2020, 25(1): 39-41.
[13]	李松, 张娟. 替诺福韦酯对乙型肝炎肝硬化患者肝纤维化状态与Th1/Th2型细胞因子的影响研究[J]. 肝脏, 2020, 25(1): 54-55.
[14]	贾瑾堂, 施文娟, 王兆勋, 田鹏飞. 乙型肝炎慢加急性肝衰竭患者血清γ干扰素水平变化的意义[J]. 肝脏, 2020, 25(1): 61-62.
[15]	王倩倩, 胡乾坤, 张毅, 方钟, 黄晨璐, 许伟, 陈良, 黄玉仙. 抗-HBc半定量水平联合早期病毒学应答预测干扰素治疗慢性乙型肝炎的疗效[J]. 肝脏, 2019, 24(9): 1002-1006.